On the contrary, miR-16 has been shown to be a tumor suppressant in NPC cells; it works by targetting fibroblast growth factor 2 (FGF2) in order to inactivate MAPK and PI3K/AKT signaling pathways [10]. The gene discussed is FGF2; the disease is nasopharyngeal carcinoma.